Endometrial Trials
Select trial for more information
Area under investigation=true,Endometrial cancer
Tumor
Advanced solid tumors (breast cancer, BTCs, ovarian cancer, endometrial cancer, squamous NSCLC)
Trial Identifier
NCT05123482
Phase
I/IIa
Regimen
Puxitatug samrotecan monotherapy; puxitatug samrotecan + rilvegostomig; puxitatug samrotecan + rilvegostomig + palacaparib
B7-H4-selected advanced/metastatic endometrial cancer
NCT07044336
III
Puxitatug samrotecan; doxorubicin/paclitaxel
HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent endometrial cancer
NCT06989112
T-DXd + (rilvegostomig or pembrolizumab); chemotherapy + pembrolizumab
fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.
HER2-expressing (IHC 3+/2+) endometrial cancer
NCT07022483
T-DXd; chemotherapy
fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world. This study is sponsored by Daiichi Sankyo, Inc.
Advanced solid tumors (advanced/metastatic ovarian cancer, HR+/HER2- breast cancer, TNBC, pancreatic cancer, prostate cancer, NSCLC, SCLC, gastric cancer, biliary cancer, cervical cancer, endometrial cancer, CRC, bladder cancer)
NCT04644068
Saruparib; saruparib + paclitaxel; saruparib + carboplatin ± paclitaxel; saruparib + T-DXd; saruparib + Dato-DXd; saruparib + camizestrant
Advanced solid tumors (endometrial, gastric, mCRPC, ovarian, colorectal, metastatic urothelial carcinoma, BTCs)
NCT05489211
II
Dato-DXd; Dato-DXd + capecitabine or 5-FU; Dato-DXd + prednisone or prednisolone; Dato-DXd + carboplatin + bevacizumab followed by Dato-DXd + bevacizumab; Dato-DXd + bevacizumab + (5-FU + leucovorin or capecitabine); Dato-DXd+ 5-FU/leucovorin or capecitabine + bevacizumab; Dato-DXd + rilvegostomig or carboplatin/cisplatin
